News

JNJ

Portola Gets FDA Accelerated Approval for Andexxa to Treat Life-Threatening Bleeding

Edward Kim | Equities.com |

Points for persistence as the FDA had initially rejected the drug in 2016.


3 Top Biopharma Companies for Second Half of 2018

Todd William | Equities.com |

Allergan, Pfizer, and Johnson & Johnson are poised to make big moves.


​Top Picks for Defensive Stocks

MoneyShow | Equities.com |

Defensive investments are ones that tend to either move opposite the market or have little to no correlation to it at all.


Janssen's Invokana Improves Kidney Function in Patients with Type 2 Diabetes and Chronic Kidney Disease

Edward Kim | Equities.com |

Data presented today at National Kidney Foundation's Spring Clinical Meetings.


Janssen Gets FDA Approval for New Prostate Cancer Drug

Edward Kim | Equities.com |

Phase 3 results showed 72% reduced risk of distant metastasis or death.


​UPS: A Buffett Bet that Keeps Delivering

MoneyShow | Equities.com |

UPS plans to deliver more than 750 million packages globally in the 25 days between Thanksgiving and New Year's Eve.


​Why J&J, Pfizer and Amgen Are Strong Pharma Picks

MoneyShow | Equities.com |

Big Pharma has deep pockets, growth through new drugs and price increases and strong balance sheets.


Stocks Race Higher as Earnings Season Kicks

Adam Sarhan | Equities.com |

The market went from being extended to being very extended as buyers continued to show up and aggressively accumulate stocks.


​Vanguard High Dividend ETF for Uncertain Markets

MoneyShow | Equities.com |

Two major factors are making dividends a popular investment focus right now.


​An ETF for Global Healthcare

MoneyShow | Equities.com |

Few necessities are as vital as health care.


Sponsored Financial Content

Market Movers